EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting sterylglucosidase 1 attenuates virulence and enables immune protection against Candida albicans

Gabriel S Matos, Vanessa Karina Kolasinski, Samyr M Querobino, Caroline Mota Fernandes, Luiz Alberti, Caroline Correa de Almeida, Anthony J Wells, Kathryn Takemura, Kyunghun Min, James B Konopka iD, Brian M Peters iD, Michael V Airola und 2 weitere

mBio · 11.11.2026

DOI: 10.1128/mbio.02310-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, online erschienen am 11.11.2026. Verfasst von Gabriel S Matos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, U.S. Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sterylglucosidases are fungus-specific enzymes that regulate ergosterol 3-β-D-glucoside (Erg-SG) homeostasis and represent promising targets for antifungal intervention. Previous studies demonstrated that sterylglucosidases from Cryptococcus neoformans and Aspergillus fumigatus contribute to fungal virulence, and that deletion of these enzymes elicits protective immunity. However, whether sterylglucosidase-mediated pathways similarly influence Candida albicans pathogenicity remains unknown. Here, we identified C. albicans Sgl1 as a bona fide sterylglucosidase that selectively hydrolyzes Erg-SG but not fungal glucosylceramide. Deletion of SGL1 resulted in marked Erg-SG accumulation without altering glucosylceramide levels, confirming its conserved role in sterylglucoside homeostasis. Although the Δ sgl 1 mutant displayed largely preserved growth, morphogenesis, and stress adaptation, it exhibited impaired biofilm formation. Biochemical characterization, inhibitor profiling, and structural analyses revealed marked species-specific inhibitor susceptibility among fungal sterylglucosidases despite highly conserved overall architecture and catalytic machinery. Structural modeling and docking studies identified differences in ligand positioning and active-site interactions that likely contribute to these divergent pharmacological responses. Functionally, loss of SGL1 significantly attenuated virulence in a murine model of systemic candidiasis. Importantly, vaccination with heat-killed Δ sgl 1 cells conferred 70% protection against lethal systemic challenge and markedly reduced kidney fungal burden, providing the first evidence that sterylglucosidase-dependent vaccination can induce protective immunity against a non-pulmonary fungal infection. Collectively, these findings establish C. albicans Sgl1 as a conserved regulator of sterylglucoside homeostasis, fungal pathogenicity, and host protection, and identify fungal sterylglucosidases as promising targets for antifungal drug and immunotherapy development. IMPORTANCE Fungal infections are associated with substantial morbidity and mortality, yet effective immunotherapies and novel antifungal targets remain limited. Candida albicans is a major cause of invasive and mucosal fungal disease, highlighting the need for new therapeutic strategies. Here, we identify the fungus-specific sterylglucosidase Sgl1 as a conserved regulator of ergosterol 3-β-D-glucoside homeostasis and a critical determinant of C. albicans pathogenicity. We further demonstrate that fungal sterylglucosidases exhibit distinct species-specific pharmacological responses despite conserved structural frameworks, revealing opportunities for rational antifungal drug design. Importantly, deletion of SGL1 attenuated virulence and enabled protective vaccination against lethal systemic candidiasis, providing the first evidence that targeting sterylglucoside metabolism can elicit protective immunity against a non-pulmonary fungal pathogen. Together, these findings identify Candida albicans Sgl1 as a promising target for antifungal drug and immunotherapy development.

Schlagwörter

Stichwörter der Autor:innen

Candida albicansantifungal drug discoveryergosterol 3-β-D-glucosidefungal virulenceimmune protectionsterylglucosidase

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
  • Department of Clinical Pharmacy and Translational Science Pharmacy, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Department of Microbiology, Immunology, and Biochemistry, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, New York, USA.
  • Institute of Chemical Biology and Drug Discovery (ICB&DD), Stony Brook, New York, USA.
  • Division of Infectious Diseases, School of Medicine, Stony Brook University, Stony Brook, New York, USA.

ORCID-Profile: James B Konopka, Brian M Peters, Maurizio Del Poeta, Nivea Pereira de Sa

Förderung

  • National Institute of Allergy and Infectious Diseases
  • U.S. Department of Veterans Affairs

Zitieren

APA

Matos, G. S., Kolasinski, V. K., Querobino, S. M., Fernandes, C. M., Alberti, L., de Almeida, C. C., Wells, A. J., Takemura, K., Min, K., Konopka, J. B., Peters, B. M., Airola, M. V., Del Poeta, M., & Pereira de Sa, N. (2026). Targeting sterylglucosidase 1 attenuates virulence and enables immune protection against Candida albicans. mBio. https://doi.org/10.1128/mbio.02310-26

Vancouver

Matos GS, Kolasinski VK, Querobino SM, Fernandes CM, Alberti L, de Almeida CC, et al. Targeting sterylglucosidase 1 attenuates virulence and enables immune protection against Candida albicans. mBio. 2026. doi:10.1128/mbio.02310-26

BibTeX
@article{Matos2026,
  author = {Matos, Gabriel S and Kolasinski, Vanessa Karina and Querobino, Samyr M and Fernandes, Caroline Mota and Alberti, Luiz and de Almeida, Caroline Correa and Wells, Anthony J and Takemura, Kathryn and Min, Kyunghun and Konopka, James B and Peters, Brian M and Airola, Michael V and Del Poeta, Maurizio and Pereira de Sa, Nivea},
  title = {Targeting sterylglucosidase 1 attenuates virulence and enables immune protection against Candida albicans},
  journal = {mBio},
  year = {2026},
  doi = {10.1128/mbio.02310-26}
}
Kostenlos starten →